Section Arrow
MGNX.NASDAQ
- MacroGenics
Quotes are at least 15-min delayed:2025/03/28 00:17 EDT
Last
 1.48
-0.08 (-5.13%)
Day High 
1.5407 
Prev. Close
1.56 
1-M High
2.565 
Volume 
949.92K 
Bid
1.5
Ask
1.57
Day Low
1.46 
Open
1.53 
1-M Low
1.55 
Market Cap 
98.42M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 2.02 
20-SMA 2.18 
50-SMA 2.59 
52-W High 19.5408 
52-W Low 1.46 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.07/-2.92
Enterprise Value
131.02M
Balance Sheet
Book Value Per Share
1.84
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
148.34M
Operating Revenue Per Share
1.89
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
OCEAOcean Biomedical0.078-0.0057-6.81%-- 
DRMADermata Therapeutics Inc.1.42+0.07+5.19%-- 
ONCOOnconetix Inc0.1077+0.0017+1.60%-- 
RGLSRegulus Therapeutics1.5+0.21+16.28%-- 
NKTXNkarta1.97+0.6+43.80%-- 
Quotes are at least 15-min delayed:2025/03/28 00:17 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.